506 related articles for article (PubMed ID: 12065702)
1. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task.
Varvel SA; Cravatt BF; Engram AE; Lichtman AH
J Pharmacol Exp Ther; 2006 Apr; 317(1):251-7. PubMed ID: 16352706
[TBL] [Abstract][Full Text] [Related]
3. The enzymatic inactivation of the fatty acid amide class of signaling lipids.
Cravatt BF; Lichtman AH
Chem Phys Lipids; 2002 Dec; 121(1-2):135-48. PubMed ID: 12505696
[TBL] [Abstract][Full Text] [Related]
4. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia.
Lichtman AH; Shelton CC; Advani T; Cravatt BF
Pain; 2004 Jun; 109(3):319-327. PubMed ID: 15157693
[TBL] [Abstract][Full Text] [Related]
5. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
Cravatt BF; Demarest K; Patricelli MP; Bracey MH; Giang DK; Martin BR; Lichtman AH
Proc Natl Acad Sci U S A; 2001 Jul; 98(16):9371-6. PubMed ID: 11470906
[TBL] [Abstract][Full Text] [Related]
6. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
Bisogno T; Melck D; De Petrocellis L; Bobrov MYu ; Gretskaya NM; Bezuglov VV; Sitachitta N; Gerwick WH; Di Marzo V
Biochem Biophys Res Commun; 1998 Jul; 248(3):515-22. PubMed ID: 9703957
[TBL] [Abstract][Full Text] [Related]
7. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase.
Huitron-Resendiz S; Sanchez-Alavez M; Wills DN; Cravatt BF; Henriksen SJ
Sleep; 2004 Aug; 27(5):857-65. PubMed ID: 15453543
[TBL] [Abstract][Full Text] [Related]
9. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.
Long JZ; Nomura DK; Vann RE; Walentiny DM; Booker L; Jin X; Burston JJ; Sim-Selley LJ; Lichtman AH; Wiley JL; Cravatt BF
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20270-5. PubMed ID: 19918051
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
13. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors.
Wise LE; Shelton CC; Cravatt BF; Martin BR; Lichtman AH
Eur J Pharmacol; 2007 Feb; 557(1):44-8. PubMed ID: 17217945
[TBL] [Abstract][Full Text] [Related]
14. Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release.
Lee SH; Ledri M; Tóth B; Marchionni I; Henstridge CM; Dudok B; Kenesei K; Barna L; Szabó SI; Renkecz T; Oberoi M; Watanabe M; Limoli CL; Horvai G; Soltesz I; Katona I
J Neurosci; 2015 Jul; 35(27):10039-57. PubMed ID: 26157003
[TBL] [Abstract][Full Text] [Related]
15. Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors.
Cheer JF; Cadogan AK; Marsden CA; Fone KC; Kendall DA
Neuropharmacology; 1999 Apr; 38(4):533-41. PubMed ID: 10221757
[TBL] [Abstract][Full Text] [Related]
16. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid.
Di Marzo V; Griffin G; De Petrocellis L; Brandi I; Bisogno T; Williams W; Grier MC; Kulasegram S; Mahadevan A; Razdan RK; Martin BR
J Pharmacol Exp Ther; 2002 Mar; 300(3):984-91. PubMed ID: 11861807
[TBL] [Abstract][Full Text] [Related]
17. A second fatty acid amide hydrolase with variable distribution among placental mammals.
Wei BQ; Mikkelsen TS; McKinney MK; Lander ES; Cravatt BF
J Biol Chem; 2006 Dec; 281(48):36569-78. PubMed ID: 17015445
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain.
Glaser ST; Gatley SJ; Gifford AN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1088-97. PubMed ID: 16278311
[TBL] [Abstract][Full Text] [Related]
20. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
